SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

09 May 2023 Evaluate
A slight decline in the revenue of Rs. 28362.70 millions was seen for the March 2023 quarter as against Rs. 28553.90 millions during year-ago period.The Total Profit for the quarter ended March 2023 of Rs. 1190.10 millions grew from Rs.-358.90 millionsA decline of 3174.80 millions was observed in the OP in the quarter ended March 2023 from 5171.50 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 28362.70 28553.90 -0.67 112588.30 117716.70 -4.36 112588.30 117716.70 -4.36
Other Income 553.00 161.50 242.41 912.60 1504.20 -39.33 912.60 1504.20 -39.33
PBIDT 3174.80 5171.50 -38.61 11739.20 4261.30 175.48 11739.20 4261.30 175.48
Interest 294.40 245.80 19.77 984.40 734.70 33.99 984.40 734.70 33.99
PBDT 2880.40 4925.70 -41.52 10754.80 3526.60 204.96 10754.80 3526.60 204.96
Depreciation 1462.00 1310.20 11.59 5483.40 5141.90 6.64 5483.40 5141.90 6.64
PBT 1418.40 3615.50 -60.77 5271.40 -1615.30 -426.34 5271.40 -1615.30 -426.34
TAX 228.30 3974.40 -94.26 1019.30 271.70 275.16 1019.30 271.70 275.16
Deferred Tax -25.90 3419.40 -100.76 60.40 -306.30 -119.72 60.40 -306.30 -119.72
PAT 1190.10 -358.90 -431.60 4252.10 -1887.00 -325.34 4252.10 -1887.00 -325.34
Equity 910.00 909.00 0.11 910.00 909.00 0.11 910.00 909.00 0.11
PBIDTM(%) 11.19 18.11 -38.20 10.43 3.62 188.03 10.43 3.62 188.03

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×